Erectile Dysfunction
Conditions
Keywords
Erectile Dysfunction, PDE5 inhibitor, Sexual Dysfunction
Brief summary
The purpose of this phase I/IIa study is to assess the safety and tolerability profile of TR399 in healthy volunteers and erectile dysfunction patients. This study will be conducted via a single-arm and open-label fashion.
Detailed description
Several oral medications containing PDE5 inhibitors, including sildenafil (Viagra®, Pfizer), vardenafil (Levitra®, Bayer) and tadalafil (Cialis®, Lilly), have been marketed for the treatment of ED. Many considerations should be taken before patients are prescribed with PDE5 inhibitor medications, which may cause systemic side effects and should not be taken with nitrates or alpha-blockers. The active pharmaceutical ingredient (API) of TR399 is 5% Vardenafil HCl·3H2O. Non-clinical studies have shown that the topical use of TR399 can enhance erection and sexual behavior in animal models without causing irritancy and phototoxicity. This study is designed as a single-arm and open-label fashion in order to explore the safety and PK of TR399 in healthy volunteers, as well as the safety, PK and efficacy of TR399 in patients with ED.
Interventions
DRUGTR-399 (5% Vardenafil HCl·3H2O, topical gel)
5% Vardenafil HCl·3H2O, topical gel, 2 drops (50ul, 2.5mg), q.d.
Sponsors
A2 Healthcare Taiwan Corporation
Tritech Biopharmaceuticals Co., Ltd.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
20 Years to 70 Years
Healthy volunteers
Yes
Inclusion criteria
* Phase I 1. Male aged between 20\ 40 years old ; 2. Physically and mentally healthy subjects as confirmed by an interview, medical history, clinical examination, and electrocardiogram; 3. Body mass index (BMI) between 18.5 and 27, inclusive, (BMI will be calculated as weight in kilogram \[kg\]/height in meters2 \[m2\]); 4. Clinically normal, including non-clinical significant abnormal, hematology, biochemistry and urinalysis determinations based on investigator's discretion; 5. Subject is willing and able to comply with study procedures and has signed informed consent. 6. With Erectile Function domain of the IIEF score of 25\ 30 * Phase IIa 1. Male aged between 20\ 70 years old ; 2. Diagnosed and confirmed ED for at least 6 months, defined as the inability to achieve and maintain an erection of the penis sufficient to complete satisfactory sexual intercourse by the National Institutes of Health (NIH) consensus report 1993; 3. With Erectile Function domain of the IIEF score of 13\ 24; 4. Stable relationship for more than 3 months; 5. At least 4 sexual intercourse attempts at 4 different days during 4-week period prior the screening; 6. With a testosterone level ≥ 240 ng/dL (either naturally or through androgen replacement therapy); 7. Subject is willing and able to comply with study procedures and has signed informed consent.
Exclusion criteria
* Phase I 1. Known or suspected allergy, hypersensitivity, or intolerance to any ingredients of study product 2. Subject who has a history or evidence of a medical condition that would expose him to an undue risk of a significant adverse event or interfere with the assessments of safety or pharmacodynamics variables during the course of the trial, including but not limited to hepatic, renal, respiratory, cardiovascular, endocrine, immune, neurological, musculoskeletal or hematological disease as determined by the clinical judgment of the investigator 3. Subject has received any investigational agent within 4 weeks prior to the screening visit 4. Subject has taken or potentially takes any prescription medication and/or over-the-counter medication from 1 week prior to the screening visit to the end of treatment (Day 15) 5. Sexual partner is a pregnant or lactating female or a female with childbearing potential not taking reliable contraceptive methods during study period Note: Acceptable contraceptive forms include 1. Established use of oral, injected or implanted hormonal methods of contraception 2. Placement of an intrauterine device (IUD) or intrauterine system (IUS) 3. Barrier methods of contraception: Condom or Occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository 6. Use of PDE-5 inhibitors within the last 2 weeks prior to the screening visit 7. Use of alpha blockers or nitrates within 2 weeks prior to the screening visit 8. Subject who has prolongation of QT interval \>500 ms (long QT syndrome) 9. Any of the following hematologic abnormalities: 1. Hemoglobin \< 10.0 g/dL 2. ANC \< 1,500/μL, 3. Platelets \< 75,000 /μL 10. Any of the following serum chemistry abnormalities: 1. Total bilirubin \> 1.5 × ULN, 2. gamma-GT \> 2.5 x ULN, 3. Alk-P \> 2.5 x ULN, 4. Serum albumin \< 3.0 g/dL, e Any other ≥ Grade 2 laboratory abnormality (based on CTCAE) at Screening visit (other than those listed above) 11. With history of stroke, myocardial infarction, or Coronary Artery Bypass Graft (CABG) surgery within the last 6 months prior to the screening visit 12. With history of cardiac failure (NYHA class 2 or above), unstable angina, or life-threatening arrhythmia within the last 6 months prior to the screening visit Note: NYHA = New York Heart Association 13. With blood pressures as systolic blood pressure \<90mmHg or \> 170mmHg or diastolic blood pressure \<50mmHg or \> 120 mmHg 14. History of orthostatic hypotension Note: Orthostatic hypotension is defined as a decrease in systolic blood pressure of 20 mm Hg or a decrease in diastolic blood pressure of 10 mm Hg. 15. History of syncope 16. Hereditary degenerative retinal disorders 17. History of loss of vision because of NAION (Non-arteritic anterior ischemic optic neuropathy), temporary or permanent loss of vision 18. Skin diseases, infection or cuts in penile area 19. History of psychiatric disorder 20. History of spinal cord injury 21. Use of HIV protease inhibitors (strong cytochrome P450 CYP3A4 inhibitors), such as indinavir or ritonavir within 2 weeks prior to the screening visit 22. History of left ventricular outflow obstruction, such as aortic stenosis and hypertrophic cardiomyopathy 23. With any cardiovascular disorder that is not suitable for sexual activities. 24. Use of antiarrhythmic agents class IA (such as quinidine, or procainamide) and class III (such as amiodarone or sotalol) within 2 weeks prior to the screening visit 25. With priapism, such as sickle cell anemia, multiple myeloma or leukemia * Phase IIa 1. Known or suspected allergy, hypersensitivity, or intolerance to any ingredients of study product 2. Participated in another clinical trial and received any investigational drug within four weeks prior to the screening visit 3. Impaired hepatic function defined as alanine aminotransferase/aspartate aminotransferase (ALT/AST) or alkaline phosphatase (ALP) at least 2.5 times upper referenced limit 4. Impaired renal function defined as serum-creatinine at least 1.3 mg/dL (at least 115 mmol/L) 5. With history of stroke, myocardial infarction, or Coronary Artery Bypass Graft (CABG) surgery within the last 6 months prior to the screening visit 6. With history of cardiac failure (NYHA class 2 or above), unstable angina, or life-threatening arrhythmia within the last 6 months prior to the screening visit Note: NYHA = New York Heart Association 7. With blood pressures as systolic blood pressure \<90mmHg or \> 170mmHg or diastolic blood pressure \<50mmHg or \> 120 mmHg 8. With any uncontrolled illness or a history of any illness judged by the investigator that entering the trial may be detrimental to the patient 9. Current treatment with systemic corticosteroids 10. History of prostatectomy due to prostate cancer, including nerve-sparing techniques 11. Use of alpha blockers or nitrates within 4 weeks prior to the screening visit 12. Use of PDE-5 inhibitor, or other treatments for erectile dysfunction within the last 4 weeks prior to the screening visit 13. Sexual partner is a pregnant or lactating female or a female with childbearing potential not taking reliable contraceptive methods during study period Note: Acceptable contraceptive forms include 1. Established use of oral, injected or implanted hormonal methods of contraception 2. Placement of an intrauterine device (IUD) or intrauterine system (IUS) 3. Barrier methods of contraception: Condom or Occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository 14. ED due to structural abnormality of the penis 15. With a history of HIV infection Note: HIV = Human Immunodeficiency Virus 16. Subject who has prolongation of QT interval \>500 ms (long QT syndrome) 17. Any of the following hematologic abnormalities: 1. Hemoglobin \< 10.0 g/dL 2. ANC \< 1,500/μL, 3. Platelets \< 75,000 /μL 18. Any of the following serum chemistry abnormalities: 1. Total bilirubin \> 1.5 × ULN, 2. gamma-GT \> 2.5 x ULN, 3. Alk-P \> 2.5 x ULN, 4. Serum albumin \< 3.0 g/dL, e Any other ≥ Grade 2 laboratory abnormality (based on CTCAE) at Screening visit (other than those listed above) 19. History of orthostatic hypotension Note: Orthostatic hypotension is defined as a decrease in systolic blood pressure of 20 mm Hg or a decrease in diastolic blood pressure of 10 mm Hg 20. History of syncope 21. Hereditary degenerative retinal disorders 22. History of loss of vision because of NAION (Non-arteritic anterior ischemic optic neuropathy), temporary or permanent loss of vision 23. Skin diseases, infection or cuts in penile area 24. History of psychiatric disorder 25. History of spinal cord injury 26. Use of HIV protease inhibitors (strong cytochrome P450 CYP3A4 inhibitors), such as indinavir or ritonavir, within 2 weeks prior to the screening visit 27. History of left ventricular outflow obstruction, such as aortic stenosis and hypertrophic cardiomyopathy 28. With any cardiovascular disorder that is not suitable for sexual activities. 29. Use of antiarrhythmic agents class IA (such as quinidine, or procainamide) and class III (such as amiodarone or sotalol), within 2 weeks prior to the screening visit 30. With priapism, such as sickle cell anemia, multiple myeloma or leukemia
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Safety evaluation of TR399 assessed by Incidence of AEs and SAEs | 24 days | Phase I Incidence of AEs and SAEs |
| Safety and efficacy evaluation of TR399 assessed by change from baseline to the last evaluation visit during the treatment period in score of IIEF-15 Erectile Function domain | 83 days | Phase IIa Change from baseline to the last evaluation visit during the treatment period in score of IIEF-15 Erectile Function domain |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Safety evaluation of TR399 assessed by Time of maximum concentration (Tmax) | 24 days | PK profiles - Time of maximum concentration (Tmax) will be measured for safety evaluation of TR399 of Phase I |
| Change from baseline to post-treatment visits in score of IIEF-15 Erectile Function domain | 83 days | Score of IIEF-15 Erectile Function will be assessed for efficacy evaluation of TR399 of Phase IIa |
| Change from baseline to post-treatment visits in SEP Question 2 | 83 days | SEP Question 2 will be assessed for efficacy evaluation of TR399 of Phase IIa |
| Change from baseline to post-treatment visits in SEP Question 3 | 83 days | SEP Question 3 will be assessed for efficacy evaluation of TR399 of Phase IIa |
| Safety evaluation of TR399 assessed by Maximum Plasma Concentration (Cmax) | 24 days | PK profiles - Maximum Plasma Concentration (Cmax) will be measured for safety evaluation of TR399 of Phase I |
| Incidence of AEs and SAEs | 83 days | Incidence of AEs and SAEs will be assessed for safety evaluation of TR399 of Phase IIa |
| Safety evaluation of TR399 assessed by Maximum Plasma Concentration (Cmax) for the first 6 evaluable ED patients | 45 days | PK profiles - Maximum Plasma Concentration (Cmax) will be measured for safety evaluation of TR399 of Phase IIa |
| Safety evaluation of TR399 assessed by Area Under the Curve (AUC) for the first 6 evaluable ED patients | 45 days | PK profiles - Area Under the Curve (AUC) will be measured for safety evaluation of TR399 of Phase IIa |
| Safety evaluation of TR399 assessed by Time of maximum concentration (Tmax) for the first 6 evaluable ED patients | 45 days | PK profiles - Time of maximum concentration (Tmax) will be measured for safety evaluation of TR399 of Phase IIa |
| Changes from baseline to post-treatment visits in vital signs, physical examination and laboratory examination results | 83 days | Vital signs, physical examination and laboratory examination results will be assessed for safety evaluation of TR399 of Phase IIa |
| Safety evaluation of TR399 assessed by Area Under the Curve (AUC) | 24 days | PK profiles - Area Under the Curve (AUC) will be measured for safety evaluation of TR399 of Phase I |
Countries
Taiwan
Contacts
Primary ContactChia-Chi Lai
Backup ContactYee-Chien Liu
Outcome results
None listed